Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283238 | 0.90 | ABL1 (0.35) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1283555 | 0.89 | ABL1 (0.34) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1282424 | 0.89 | ABL1 (0.37) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1283077 | 0.88 | ABL1 (0.36) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1282659 | 0.88 | ABL1 (0.36) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1282554 | 0.88 | ABL1 (0.37) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1282907 | 0.88 | ABL1 (0.36) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17243951 | 0.87 | ABL1 (0.37) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1283232 | 0.87 | ABL1 (0.35) | ABL1 | |
| SCHEMBL1283144 | 0.87 | ABL1 (0.35) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | claimed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | claimed |
| US-20170007615-A1 | Antibacterial Compounds | SPERO GYRASE, INC. | 2017-01-12 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NISCH, LSS | FGFR3 3719/4885KDR 4799/4885ABL1 537/4885 |
| US-20170007615-A1 | Antibacterial Compounds | CLPP, MRPL21, RELA | FGFR3 4167/4885KDR 4578/4885ABL1 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.